A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

Inclusion Criteria

• Inclusion Criteria: For Parts A, B, and C: - Participants must have one of the following histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumor types: - High-grade serous epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer - HER2-negative, HR positive breast cancer - Triple-negative breast cancer (TNBC) - Endometrial carcinoma - Non-small cell lung cancer (Squamous cell carcinoma [SqCC], Adenocarcinoma [AC]) - Cholangiocarcinoma or gallbladder carcinoma - Adenoid cystic carcinoma (ACC) For Part D: Participants must have histologically or cytologically confirmed locally advanced unresectable or metastatic TNBC. For Part E: - Cohort E1: Participants must have histologically or cytologically confirmed locally advanced unresectable or metastatic TNBC and must have CPS≥10 by local testing - Cohort E2: Participants must have histologically or cytologically confirmed locally advanced unresectable or metastatic TNBC and must have CPS<10 by local testing - Cohort E3: Participants must have triple negative breast cancer with residual disease following neoadjuvant therapy and definitive surgery - Parts A and B: Participants must have disease that is relapsed or refractory or be intolerant to SOC therapies, and, in the judgement of the investigator, should have no appropriate SOC therapeutic option - Part C: Participants must have disease that is relapsed or refractory or be intolerant to SOC therapies. - Part D and E1/E2: Participants must have had no prior treatment for locally advanced unresectable or metastatic TNBC - Part E3: Participants must have completed at least 6 cycles of neoadjuvant therapy for locally advanced unresectable or metastatic TNBC - Tumor tissue is required for enrollment. - Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 - Measurable disease per RECIST version 1.1 at baseline (not applicable for E3 participants). Exclusion Criteria: - History of another malignancy within 3 years before the first dose of study drug. Any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death. - Known active central nervous system metastases. Participants with previously treated brain metastases may participate provided they: - are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment - have no new or enlarging brain metastases - and are off corticosteroids prescribed for symptoms associated with brain metastases for at least 7 days prior to the first dose of study treatment. - Carcinomatous meningitis - Previous receipt of an MMAE-containing agent or an agent targeting B7-H4 - Pre-existing neuropathy ≥ Grade 2 per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 - Corneal disease or injury requiring treatment or active monitoring